Limits...
Assessing gastroenterologist and patient acceptance of biosimilars in ulcerative colitis and Crohn's disease across Germany

View Article: PubMed Central - PubMed

ABSTRACT

Objectives: This study examined gastroenterologists’ motivation for prescribing biosimilars, assessed their treatment preferences in relation to prescribing behaviour, and explored patient attitudes to biosimilars.

Methods: Data were taken from the Adelphi Real World Biosimilars Programme, a real-world, cross-sectional study undertaken in 2015–2016 with German gastroenterologists and patients with ulcerative colitis or Crohn’s disease. Gastroenterologists provided data on their prescribing behaviour and attitudes towards biosimilars, and invited the next eight eligible consecutive consulting patients to complete a detailed questionnaire. For analysis, gastroenterologists were split into ‘Investigative’, ‘Conservative’, and ‘Other’ groups.

Results: Overall, 25 gastroenterologists and 136 patients participated. Biosimilars accounted for <15% of all biologic therapies and >80% of gastroenterologists would prescribe a bio-originator rather than biosimilar as 1st line therapy if unrestricted. Patients showed some reluctance to accept biosimilars, although of those receiving biosimilars, 79% were satisfied with the current treatment of their condition, and 69% were satisfied with the control of symptoms. Although at least 35% of patients in each analysis group reported no concerns when starting treatment with a bio-originator or biosimilar, 41% of previously biologic-naïve patients prescribed a biosimilar indicated potential side effects and potential long-term problems, and 24% not knowing enough about the drug, as concerns.

Conclusion: Results demonstrate that there is reluctance from patients to accept biosimilars and the need to further educate patients who are unsure to allow them to be involved in decision making, highlighting the importance of patient and physician communication. There remains a need for further research into non-clinical switching and the long term impact of prescribing biosimilars.

No MeSH data available.


Patient concerns when first prescribed their treatment.BioSN, Patient receiving biosimilar who was previously biologic-naïve; BioSE, Patient receiving biosimilar who has experience of a bio-originator; BioOA, Patient receiving bio-originator who was initiated after February 2015; BioOB, Patient receiving bio-originator who was initiated before January 2015. “Blue”- BioSN, “orange accent 6”- BioSE, “grey”- BioOA, “orange”—BioOB.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC5391967&req=5

pone.0175826.g004: Patient concerns when first prescribed their treatment.BioSN, Patient receiving biosimilar who was previously biologic-naïve; BioSE, Patient receiving biosimilar who has experience of a bio-originator; BioOA, Patient receiving bio-originator who was initiated after February 2015; BioOB, Patient receiving bio-originator who was initiated before January 2015. “Blue”- BioSN, “orange accent 6”- BioSE, “grey”- BioOA, “orange”—BioOB.

Mentions: When patients were asked what concerns they had when first prescribed their current treatment, at least 35% of those in each analysis group reported no concerns (Fig 4). However, 41% of patients prescribed a biosimilar who had not previously received any type of biologic indicated potential side effects and potential long-term problems as a concern, and 24% of this group were also concerned that they did not know enough about the drug (Fig 4). Of those patients prescribed a biosimilar who had previously received a bio-originator, 33%, 30%, and 15% were concerned about potential long-term problems, potential side effects and not knowing enough about the drug, respectively (Fig 4). For those receiving a bio-originator, a higher proportion of those whose treatment was initiated prior to January 2015 (i.e. before the approval of biosimilars) were concerned that they didn’t know enough about the drug, while a higher proportion of those whose treatment was initiated after February 2015 were concerned that the medication was too expensive (Fig 4).


Assessing gastroenterologist and patient acceptance of biosimilars in ulcerative colitis and Crohn's disease across Germany
Patient concerns when first prescribed their treatment.BioSN, Patient receiving biosimilar who was previously biologic-naïve; BioSE, Patient receiving biosimilar who has experience of a bio-originator; BioOA, Patient receiving bio-originator who was initiated after February 2015; BioOB, Patient receiving bio-originator who was initiated before January 2015. “Blue”- BioSN, “orange accent 6”- BioSE, “grey”- BioOA, “orange”—BioOB.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC5391967&req=5

pone.0175826.g004: Patient concerns when first prescribed their treatment.BioSN, Patient receiving biosimilar who was previously biologic-naïve; BioSE, Patient receiving biosimilar who has experience of a bio-originator; BioOA, Patient receiving bio-originator who was initiated after February 2015; BioOB, Patient receiving bio-originator who was initiated before January 2015. “Blue”- BioSN, “orange accent 6”- BioSE, “grey”- BioOA, “orange”—BioOB.
Mentions: When patients were asked what concerns they had when first prescribed their current treatment, at least 35% of those in each analysis group reported no concerns (Fig 4). However, 41% of patients prescribed a biosimilar who had not previously received any type of biologic indicated potential side effects and potential long-term problems as a concern, and 24% of this group were also concerned that they did not know enough about the drug (Fig 4). Of those patients prescribed a biosimilar who had previously received a bio-originator, 33%, 30%, and 15% were concerned about potential long-term problems, potential side effects and not knowing enough about the drug, respectively (Fig 4). For those receiving a bio-originator, a higher proportion of those whose treatment was initiated prior to January 2015 (i.e. before the approval of biosimilars) were concerned that they didn’t know enough about the drug, while a higher proportion of those whose treatment was initiated after February 2015 were concerned that the medication was too expensive (Fig 4).

View Article: PubMed Central - PubMed

ABSTRACT

Objectives: This study examined gastroenterologists’ motivation for prescribing biosimilars, assessed their treatment preferences in relation to prescribing behaviour, and explored patient attitudes to biosimilars.

Methods: Data were taken from the Adelphi Real World Biosimilars Programme, a real-world, cross-sectional study undertaken in 2015–2016 with German gastroenterologists and patients with ulcerative colitis or Crohn’s disease. Gastroenterologists provided data on their prescribing behaviour and attitudes towards biosimilars, and invited the next eight eligible consecutive consulting patients to complete a detailed questionnaire. For analysis, gastroenterologists were split into ‘Investigative’, ‘Conservative’, and ‘Other’ groups.

Results: Overall, 25 gastroenterologists and 136 patients participated. Biosimilars accounted for <15% of all biologic therapies and >80% of gastroenterologists would prescribe a bio-originator rather than biosimilar as 1st line therapy if unrestricted. Patients showed some reluctance to accept biosimilars, although of those receiving biosimilars, 79% were satisfied with the current treatment of their condition, and 69% were satisfied with the control of symptoms. Although at least 35% of patients in each analysis group reported no concerns when starting treatment with a bio-originator or biosimilar, 41% of previously biologic-naïve patients prescribed a biosimilar indicated potential side effects and potential long-term problems, and 24% not knowing enough about the drug, as concerns.

Conclusion: Results demonstrate that there is reluctance from patients to accept biosimilars and the need to further educate patients who are unsure to allow them to be involved in decision making, highlighting the importance of patient and physician communication. There remains a need for further research into non-clinical switching and the long term impact of prescribing biosimilars.

No MeSH data available.